Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 31 for “"temsirolimus"”.

  1. Efficacy of Tamoxifen, Alone or in Combination with Vincristine and Temsirolimus, in in vitro and in vivo Models of Rhabdomyosarcoma

    … agent) enhances JNK phosphorylation, while temsirolimus (an emerging RMS drug currently in phase III trials) inhibits mTOR complex 1. Combining tamoxifen with either of these drugs led to increased efficacy against cell proliferation in vitro. In an alveolar RMS (ARMS) xenograft mouse model, …

    toronto-retro Repository record for Efficacy of Tamoxifen, Alone or in Combination with Vincristine and Temsirolimus, in in vitro and in vivo Models of Rhabdomyosarcoma (opens in a new tab)

  2. Ρόλος του mTOR στο κακοήθες μεσοθηλίωμα: θεραπευτικές δυνατότητες

    … and function.We hypothesized that temsirolimus, an mTOR inhibitor, would curtail experimental mesothelioma progression in vivo by limiting tumour cell growth, abrogating tumour angiogenesis and modulating immune/ inflammatory tumour milieu. Methods: We produced flank and pleural …

    greece Repository record for Ρόλος του mTOR στο κακοήθες μεσοθηλίωμα: θεραπευτικές δυνατότητες (opens in a new tab)

  3. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

    … research study the small molecule inhibitor temsirolimus targeting the PI3K/Akt /mTOR pathway has been tested in vitro in SCCHN cell lines. The initial focus of the study was the evaluation of the radiosensitizing potential of the mTOR inhibitor temsirolimus (CCI-779). Initial experiments …

    fu-berlin Repository record for CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab (opens in a new tab)

  4. Μελέτη της βιολογικής δράσης σηματοδοτικών αναστολέων σε καρδιομυοκύτταρα

    … – 2 - methylpropanoate], ή αλλιώς Temsirolimus, και της 17- allylamino - 17 demethoxygeldanamycin (17-AAG), σε καρδιομυοκύτταρα, καθώς και η σύγκριση της επίδρασής τους με εκείνην ενός χημειοθεραπευτικού παράγοντα με αποδεδειγμένη καρδιοτοξική δράση, της Doxorubicin. Η μελέτη των …

    athens Repository record for Μελέτη της βιολογικής δράσης σηματοδοτικών αναστολέων σε καρδιομυοκύτταρα (opens in a new tab)

  5. Therapeutic implications of Notch signaling in ovarian cancer

    … chemotherapy and other targeted agents (e.g. temsirolimus) and as a single-agent in selected malignancies (e.g. ovarian cancer). The results presented herein have demonstrated that RO4929097 has a tolerable safety profile both in combination with temsirolimus in patients with solid tumors and …

    sevilla Repository record for Therapeutic implications of Notch signaling in ovarian cancer (opens in a new tab)

  6. An Innovative Phase I Trial Design Allowing For The Identification of Multiple Potential Maximum to lerated Doses With Combination Therapy of Targeted Agents

    … The two drugs combined in our phase I trial are temsirolimus and bevacizumab. Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway which is fundamental for tumor growth and metastasis. One mechanism of tumor resistance to antiangiogenic therapy is …

    uthsc Repository record for An Innovative Phase I Trial Design Allowing For The Identification of Multiple Potential Maximum to lerated Doses With Combination Therapy of Targeted Agents (opens in a new tab)

  7. The Effect of Molecular Targeted Agents used in Combination with Chemotherapy to Inhibit the Repopulation of Tumour Cells and Xenografts

    … chemotherapy in combination with gefitinib or temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, showed that concurrent scheduling of combined treatment was more effective at delaying regrowth of xenografts than sequential treatment; this was likely due to dominant effects on the …

    toronto-retro Repository record for The Effect of Molecular Targeted Agents used in Combination with Chemotherapy to Inhibit the Repopulation of Tumour Cells and Xenografts (opens in a new tab)

  8. Die Analyse der Inhibition des Monozyten chemotaktischen Proteins-1 (MCP-1) und der Stimulation durch MCP-1 auf die Koloniebildung und die Zytokinexpression von Plattenepithelkarzinomen der Kopf-Hals-Region im FLAVINO-Assay

    … von Cisplatin, Docetaxel, Cilengitide und Temsirolimus wurde die Expression der untersuchten Zytokine in den Kulturüberständen der HNSCC unterschiedlich moduliert. Cisplatin und MCP-1 supprimierten die Koloniebildung signifikant, während unter Docetaxel und Temsirolimus eine insignifikante …

    qucosa-diss

  9. Prognosefaktoren und Sequenztherapiestrategien der zielgerichteten Therapie beim metastasierten Nierenzellkarzinom

    … eines sequentiellen Einsatzes des mTORi Temsirolimus nach Versagen einer VEGFi Therapie untersucht werden (Weikert, Kempkensteffen et al. 2011), nicht zuletzt weil es bis dato lediglich eine prospektiv-evaluierte Empfehlung zum Einsatz als Erstlinientherapie bei „poor prognosis“ Patienten …

    fu-berlin Repository record for Prognosefaktoren und Sequenztherapiestrategien der zielgerichteten Therapie beim metastasierten Nierenzellkarzinom (opens in a new tab)

  10. Identification of novel strategies to radiosensitise tumour cells

    … cells. Our studies with the rapamycin analogue temsirolimus, already in the clinic for the treatment of various cancers, can be a potential candidate as a radiosensitiser for RCC cells. Overall, these finding led us to investigate further whether autophagy inducing compounds, which are either in …

    oxford Repository record for Identification of novel strategies to radiosensitise tumour cells (opens in a new tab)

  11. Combating Resistance To Epidermal Growth Factor Recpetor Inhibitors In Triple Negative Breast Cancer

    … phosphorylated. While inhibiting mTOR with temsirolimus (TEM) decreased mTOR signaling, EGFR signaling pathways remained activated and the TNBC cell lines continued to proliferate. However, dual treatment with TEM and GEF synergistically decreased cell viability in TNBC cells. Interestingly, …

    wayne-thes Repository record for Combating Resistance To Epidermal Growth Factor Recpetor Inhibitors In Triple Negative Breast Cancer (opens in a new tab)

  12. The role of mTOR signaling and autophagy in stress driven depressive pathology

    … της χρήσης του εγκεκριμένου από τον FDA φαρμάκου Temsirolimus (CCI-779), επηρεάζει την σχέση μεταξύ αυτοφαγίας και NLRP3 φλεγμονοσώματος, καθώς επίσης και την στρεσοεπαγόμενη γνωσιακή διαταραχή, και διαταραχή της διάθεσης. Τα αποτελέσματά μας δείχνουν ότι το χρόνιο στρες αύξησε το άγχος και την …

    athens Repository record for The role of mTOR signaling and autophagy in stress driven depressive pathology (opens in a new tab)

  13. Rituximab Effektivität in Mantelzelllymphomen: Additive und antagonistische Effekte mit Standardchemotherapeutika und Molekularen Substanzen

    … von einem anderen mTOR-Inhibitor, Temsirolimus, und Rituximab in Patienten mit rezidivierten und refraktären MCL von Vorteil sein kann. Bei der Kombinationstherapie von Rituximab und Flavopiridol wurden zum Teil additive und zum Teil antagonistische Effekte beobachtet. Bei den …

    lmu-germany Repository record for Rituximab Effektivität in Mantelzelllymphomen: Additive und antagonistische Effekte mit Standardchemotherapeutika und Molekularen Substanzen (opens in a new tab)

  14. Towards the Development of Preclinical Models and Subtype-Specific Therapeutics for Atypical Teratoid Rhabdoid Tumors

    … and MTOR inhibitors, rapamycin, everolimus and temsirolimus are capable of sensitizing Group 2a/b cells to radiation. This thesis work advances ATRT research on two important fronts: the much-needed development of preclinical models and the identification of novel, subtype-specific therapeutics.

    toronto-retro Repository record for Towards the Development of Preclinical Models and Subtype-Specific Therapeutics for Atypical Teratoid Rhabdoid Tumors (opens in a new tab)

  15. Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier

    … regimen. Erlotinib, canertinib, everolimus and temsirolimus were screened as potential modulators of P-gp and Bcrp1 activity. The fact that these drugs inhibit a different class of receptor population than pazopanib and vandetanib, offer a dual advantage for synergistic pharmacological effect in …

    umkc Repository record for Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier (opens in a new tab)

  16. Resistance mechanisms to mTOR inhibition in renal cancer

    … (mTOR) and two rapalogues (everolimus and temsirolimus) have been licensed for the treatment of advanced CCRCC, but resistance to treatment is a significant problem. Novel mTOR kinase inhibitors show more complete blockade of mTOR downstream targets, and greater <em>in vitro</em> anti …

    oxford Repository record for Resistance mechanisms to mTOR inhibition in renal cancer (opens in a new tab)

  17. Effektivität von neuen systemtherapeutischen Optionen bei Patienten mit metastasiertem Nierenzellkarzinom

    … therapy were primary metastasis and the use of temsirolimus. In the third-line therapy, the presence of a clear cell tumor type showed a significantly reduced risk of progression. Discussion: The introduction of new therapeutic options led to a significant extension of PFS and a reduction in …

    fu-berlin Repository record for Effektivität von neuen systemtherapeutischen Optionen bei Patienten mit metastasiertem Nierenzellkarzinom (opens in a new tab)

  18. Σύγκριση μοριακά στοχευμένων θεραπειών πρώτης γραμμής στο μεταστατικό καρκίνωμα του νεφρού: μετα-ανάλυση

    … Axitinib (AXI), cabozantinib (CAB), temsirolimus (TEM), pazopanib (PAZ), TEM/IFN and tivozanib (TIV) also prolonged OS, but not significantly (HRs 0.77, 0.80, 0.89, 0.91, 0.93 and 0.96, respectively). CAB, sunitinib (SUN), AXI, TIV, PAZ, SOR and EVE demonstrated significant …

    greece Repository record for Σύγκριση μοριακά στοχευμένων θεραπειών πρώτης γραμμής στο μεταστατικό καρκίνωμα του νεφρού: μετα-ανάλυση (opens in a new tab)

Page 1 of 2